Welcome!
PhillipCapital Research
Broker's Calls
Most sectors in STI to enjoy tailwinds in stagflation environment: PhillipCapital
With the global economy facing stagflation, the Singapore market stands out as a shelter: PhillipCapital
April 05, 2022
Broker's Calls
PhillipCapital keeps “buy” rating on Keppel amid mixed bag of progress and delays
PhillipCapital Group Research has kept a “buy” rating on Keppel Corporation with an unchanged target price of $7.07
April 04, 2022
Broker's Calls
PhillipCapital stays 'overweight' on Singapore banks after rosy results
“We remain positive on banks. Bank dividend yields are attractive with upside surprise due to excess capital ratios.”
March 09, 2022
Broker's Calls
BHG Retail REIT expected to see stable growth moving forward
Analysts from PhillipCapital and DBS Group Research believe that the worst is over for BHG Retail REIT
March 08, 2022
Broker's Calls
Analysts mixed on PropNex with warnings of 'caution ahead'
Analysts are mixed on PropNex due to caution over earnings and effect of property cooling measures
March 01, 2022
Broker's Calls
'Muted impact' from Keppel's arbitration action against SPH, focus on Sembmarine merger instead: analysts
“We expect that Keppel’s stock will remain capped until a final resolution on SPH is announced.”
February 11, 2022
Broker's Calls
PhillipCapital remains overweight on banks ahead of FY2021 results, OCBC 'most attractive'
“Valuations for OCBC are the most attractive and [have the] largest upside surprise from dividends.”
February 09, 2022
Broker's Calls
PhillipCapital lowers Frasers Centrepoint Trust's TP to $2.64 on reduced DPU estimates and higher COE
FY22 to FY26 DPU estimates have been lowered by 3% to 5.3% due to the anticipated rising cost of borrowing.
February 03, 2022
Broker's Calls
Out of the red in FY2021, 'all stars aligned' for Keppel Corp though SPH deal remains unclear: analysts
“We were a little disappointed on the lack of clarity on the timeline for its acquisition of SPH.”
January 31, 2022
Broker's Calls
Hyphens Pharma 9M21 PATMI exceeds expectations amidst speed bump in Vietnam: PhillipCapital
For the 9MFY2021 ended September, Hyphens Pharma reported PATMI of $1.09 million, 28.8% higher y-o-y
November 25, 2021